

Genomic Medicine 9




April 19-20, 2016 Silver Spring, MD

Organizing Committee:
Teri Manolio, NHGRI
Carol Bult, The Jackson Laboratory
Howard Jacob, Alpha Hudson Institute for Biotechnology



National Human Genome Research Institute





Research Funding

Research at NHGRI

Health

Education

Issues in Genetics

Newsroom

Careers & Training

About E


Español





Home > Research Funding > Research Funding Divisions > Division of Genomic Medicine > Genomic Medicine Activities > Genomic Medicine IX (GM9)

Genomic Medicine Meeting IX: Bedside to Bench - Mind the Gaps




On April 19-20, 2016, the National Human Genome Research Institute (NHGRI) will sponsor its ninth Genomic Medicine meeting - *Genomic Medicine IX: Bedside to Bench - Mind the Gaps* - at the Sheraton Silver Spring Hotel in Silver Spring, Maryland.

GM9 will focus on facilitating bedside back to bench research by focusing on one of the most vexing problems in clinical sequencing: characterizing and interpreting variants of uncertain significance (VUS).

Objectives include to:

- 1. Review examples of successful interactions between basic scientists and clinical genomicists and explore what made them successful;
- 2. Identify ways to enhance interactions between basic scientists and clinical genomicists (aka, the virtuous cycle of bench to bedside and back again);
- 3. Determine how better to integrate basic science research efforts with clinically important questions, to enhance the exploration of clinical implications of basic discoveries.


https://www.genome.gov/27564185/nhgri-genomic-medicine-ix-meeting-bedside-to-bench--mind-the-gaps/



B. Mellor, Nature 2008

From bench to bedside in genomic medicine: Lost in translation?

- Translation from model system to human, and vice versa
- Translation to patients
- Translation to practice



Focus

 GM9 will focus on a major challenge to advancing genomic medicine: characterizing and interpreting the clinical significance of variants of uncertain significance (VUS)



Objectives

 What makes for successful interactions between basic scientists and clinical genomicists?

 How can the virtuous cycle of "bench to bedside to bench again" be fostered and enhanced?

 How can we achieve better alignment of basic research efforts with clinically important questions?

Topics

- Understanding the functions of VUS and relevance to disease mechanisms
- Prediction and annotation of genomic variant function
- Biomedical ontologies for data and knowledge integration and sharing
- Facilitating bedside-back-to-bench research
- Regulatory hurdles
- Issues with payers

Bench to Bedside....



Special Thanks

- Rita Chambers, Senior Program Coordinator, Duke University
- Teji Rakhra-Burris, Program Leader, Precision Medicine, Duke University
- Elian (Elle) Silverman, Program Analyst, NHGRI
- Members of the NHGRI Genomic Medicine Working Group